RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - PRODUZIONE E CATABOLISMO DELLA BETA-AMILOIDE IN PAZIENTI CON MALATTIA DI ALZHEIMER E MILD COGNITIVE IMPAIRMENT: STUDI IN VITRO E MARKERS EX VIVO
• 2 - Aspetti biochimici e genetici del disturbo autistico.
• 3 - Modulazione dell' inizio della coagulazione nelle patologie emorragiche e trombotiche
• 4 - Iperlipidemia, Aterosclerosi e Insufficienza Renale
• 5 - Caratterizzazione biochimica e molecolare dell'interazione Von Willebrand Factor e ADAMTS-13: nuove ipotesi sulla fisiopatogenesi delle malattie microangiopatiche trombotiche
• 6 - Geni dell'angiogenesi indotti da ipossia: fattori di suscettibilità nella Sclerosi Laterale Amiotrofica ?
• 7 - Danno cardio-vascolare precoce in bambini ed adolescenti obesi :la identificazione di markers di rischio metabolici e/o genetici rende possibile la diagnosi precoce e può migliorare la qualità della vita futura.
• 8 - Studio dei meccanismi molecolari alla base dell’anomala proliferazione e funzione paratiroidea, e identificazione ed uso clinico di marcatori molecolari di carcinoma paratiroideo sporadico e familiare. Nuove acquisizione sulla prevalenza delle manifestazioni scheletriche, neuropsichiche e metaboliche dell’iperparatiroidismo primario, loro relazione con i polimorfismi del recettore del calcio ed effetti della paratiroidectomia.
• 9 - PROGRESSIONE DA MGUS A MIELOMA MULTIPLO: PATOGENESI MOLECOLARE, IDENTIFICAZIONE DI POTENZIALI MARCATORI PROGNOSTICI E SVILUPPO PRECLINICO DI RAZIONALI APPROCCI CHEMIOPREVENTIVI
• 10 - Ruolo delle adipochine, citochine infiammatorie e linfociti T regolatori nel determinismo dell’aterosclerosi accelerata e della sindrome metabolica in corso di lupus eritematoso sistemico.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • MEDICINA INTERNA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • DIAGNOSIS; SURGERY; IDENTIFICATION (analysing biological material G01N, e.g. G01N33/48; obtaining records using waves other than optical waves, in general G03B42/00)

Classificazione geografica

• Regione: Abruzzo

Bibliografia

1. Yancey PG, Bortnick AE, Kellner-Weibel G, De la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thomb Vasc Biol 2003; 23: 712–719.
2. Williams DL, Connelly MA, Temel RE, Swarnakar S, Phillips MC, De la Llera-Moya M, Rothblat GH. Scavenger receptor B1 and cholesterol trafficking. Curr Opin Lipidol 1999; 10: 329–339.
3. Brewer Jr. HB. High-Density Lipoproteins: A new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004; 24: 387-391.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–97.
5. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease: The Framingham Study. Ann Epidemiol 1992; 2: 23–28.
6. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med 1989; 321: 1311–1316.
7. Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 2000; 86: 11L-14L.
8. Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004; 43: 717-24.
9. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991; 353: 265–267.
10. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1994; 91: 9607–9611.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22.
12. Soro A, Pajukanta P, Lilja HE, Ylitalo K, Hiekkalinna T, Perola M, Cantor RM, Viikari JS, Taskinen MR, Peltonen L. Genome
Scans Provide Evidence for Low-HDL-C Loci on Chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish Families. Am J Hum Genet 2002; 70: 1333-1340.
13. Brewer HB, Santamarina-Fojo S, Hoeg JM. Disorders of lipoprotein metabolism. In Endocrinology. DeGroot LJ, Besser M, Jameson JL et al eds, WB Saunders Company, Philadelphia, 1995, pp.2731-2753.
14. Cohen JC, Wang Z, Grundy SM, et al. Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest. 1994; 94: 2377–2384.
15. Brunzell J, Deeb S. Familial lipoprotein lipase deficiency, apo CII deficiency, and hepatic lipase deficiency. In: Scriver C, Beaudet A, Sly W, Vale D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill Book Co; 2001. pp. 2789–2816.
16. Guerra R, Wang S, Grundy S, Cohen J. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A 1997; 94:4532–4537.
17. Heinecke JW, Lusis AJ. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet 1998; 62: 20-24.
18. Mackness B, Durrington PN, Mackness MI. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet 1999; 353: 468-469.
19. Navab M, Berliner GS, Hama S, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Atheroscler Thromb Vasc Biol. 1998; 21: 481–8.
20. Sampietro T, Bigazzi F, Dal Pino B, Fusaro S, Greco F, Tuoni M, Bionda A. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia. A proinflammatory condition? Circulation. 2002; 105: 11-4.
21. Van Lenten BJ, Hama S, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995; 96: 2758–67.
22. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001; 21: 481–8.
23. Navab M, Hama SY, Hough GP, et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res. 2001; 8: 1308–17.
24. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-6.
25. Brandt E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. Immunol Rev 2000; 177: 204-16.
26. von Hundelshausen P, Weber KS, Huo Y, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-7.
27. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M,Fazia M, Falco A, Cuccurullo F, Davì G. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106: 399-402.
28. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-90.
29. Ferroni P, Martini F, Cardarello CM, Gazzaniga PP, Davì G, Basili S. Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. Circulation 2003; 108: 1673-5.
30. Davì G, Falco A, Patrono C. Determinants of F2-isoprostanes biosynthesis and inhibition in man. Chem Phys Lipids 2004; 128: 149-63.
31. Navab M, Hama SY, Reddy ST, Ng CJ, Van Lenten BJ, Laks H, Fogelman AM, Ready ST. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol. 2002; 13: 363-72.
32. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002; 8: 1227-34.
33. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997; 17: 2309-15.
34. Praticò D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine. Trends Endocrinol Metab. 2001; 12: 243-7.
35. Morrow JD, Roberts LJ. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med 2002; 166: S25-30.
36. Davì G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-14.
37. Davì G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB, Ciabattoni G, Patrono C. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 3230-5.
38. Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-9.
39. Davì G, Di Minno G, Coppola A, Andria G, Cerbone AM, Madonna P, Tufano A, Falco A, Marchesani P, Ciabattoni G, Patrono C. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001; 104: 1124-8.

Parole Chiave

ATEROSCLEROSI, LIPOPROTEINE AD ALTA DENSITA', INFIAMMAZIONE, STRESS OSSIDATIVO, ATTIVAZIONE PIASTRINICA, PARAOXONASI, POLIMORFISMI GENICI